Overview
The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are:
1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose
2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients
3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms
4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2)
5) biosensors for field detection or diagnosis